您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > ZM 306416(CB676475)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
ZM 306416(CB676475)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
ZM 306416(CB676475)图片
CAS NO:690206-97-4
规格:≥98%
包装与价格:
包装价格(元)
10mg电议
25mg电议
50mg电议
100mg电议
250mg电议
500mg电议
1g电议

产品介绍
理化性质和储存条件
Molecular Weight (MW)333.74
FormulaC16H13ClFN3O2
CAS No.690206-97-4
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 67 mg/mL (200.8 mM)
Water:<1 mg/mL
Ethanol:<1 mg/mL
SMILES CodeCOC1=CC2=NC=NC(NC3=CC=C(Cl)C=C3F)=C2C=C1OC
SynonymsZM 306416; ZM-306416; CB 676475; CB676475; CB-676475; ZM306416;

Chemical Name: 4-[(4'-Chloro-2'-fluoro)phenylamino]-6,7-dimethoxyquinazoline

InChi Key: YHUIUSRCUKUUQA-UHFFFAOYSA-N

InChi Code: InChI=1S/C16H13ClFN3O2/c1-22-14-6-10-13(7-15(14)23-2)19-8-20-16(10)21-12-4-3-9(17)5-11(12)18/h3-8H,1-2H3,(H,19,20,21)

SMILES Code: COC1=CC2=NC=NC(NC3=CC=C(Cl)C=C3F)=C2C=C1OC

实验参考方法
In Vitro

In vitro activity: ZM 306416 (also known as CB 676475) is a potent inhibitor or antagonist for VEGFR1 (vascular endothelial growth factor receptor 1) tyrosine kinase with IC50 of 0.33 μM, but it was also found to be an inhibitor of EGFR with IC50 of<10 nM. Using A549-EGFRB cells for EGFRB assay, it was revealed that ZM 306416 exhibited inhibitory activity on VEGFR with IC50 value of 670 nM. When tested with human thyroid follicular cells. ZM 306416 treatment reducing VEGFR2 phosphorylation and inhibited endogenous, steady-state levels of p42/44 MAPK phosphorylation. Taken together, these results demonstrate ZM 306416's potential use in the clinic.


Kinase Assay: The activity of confirmed positives was assessed in a panel of kinases consisting of EGFR, VEGFR1, SRC and ABL kinase using a luminescence ADP production kinase assay as previously described. The potency of each compound was measured in dose response studies in 384-well format using 12 doubling dilutions in duplicate with 10 μM and 1 μM compound concentration as the upper limit. All reagents transfers were performed using the PP-384-M Personal Pipettor. Tested compounds or controls were added to the wells at a volume of 1 μL to white 384 well microtiter plates (Corning #3570, Corning, NY). Controls consisted of 1% DMSO (v/v) (high control) and 30 μM staurosporine in 1% DMSO (v/v) (low controls). The assay buffer was 25 mM Hepes/NaOH, pH 7.5 and contained 10 mM MgCl2, 2 mM TCEP, 20 mM β-Glycerol Phosphate, and 100 μM Na3VO4; for each kinase on the panel 4 μL of kinase dilution in assay buffer were added to the wells to reach a final concentration of 50 nM enzyme. Of note, the specific activity of the kinases of the panel is unknown and therefore the concentration of active enzyme in the preparation is unknown. After enzyme addition, kinase and compound were pre-incubated for 10 minutes at room temperature. Then 5 μL of a mix containing ATP and Poly(Glu, Tyr) substrates in solution in assay buffer were added to the wells both to reach a final concentration of 200 μM. After 45 minutes reaction at room temperature, 10 μL of ADP-Glo Reagent were added to each well. After 40 minutes incubation, 20 μL Kinase Detection Reagent were added followed by 60 minute incubation. The luminescence signal output was measured on the LEADseeker(TM). Dose response curves were plotted using SigmaPlot and represent the mean data from duplicates, the error bars correspond to the standard error of the regression. The low limit for calculating compound IC50 in the assay conditions was 10 nM.


Cell Assay: The anti-proliferative effect of confirmed hits was assessed against a panel of established cell lines that includes those harboring wild type EGFR (A549-EGFRB, A549 and H2030 cell lines) and those harboring the activating L858R EGFR mutation (H3255 and HCC4011 cell lines). A549-EGFRB cells were cultured as previously described. H2030, H3255 and HCC4011 cells were cultured as previously described. A549 cells were cultured in F12K media (Invitrogen Cat.# 21127-022) supplemented with 10% FBS (PAA Cat.# A15-201). The anti-proliferative effect of each compound was assessed in dose response studies in 384-well format using 12 doubling dilutions in duplicate with 10 μM and 1 μM compound concentration as the upper limit and using the Alamar Blue viability assay as previously described. Control wells consisted of 1% DMSO (v/v) (high control) and 1 μM “killer mix” in 1% DMSO (v/v) (low control). Final compound incubation time with cells was 120 hours. In dose response curves plotted using SigmaPlot 9.0 (Systat Software, San Jose, CA), the mean data from duplicates is presented and the error bars correspond to the standard error of the regression.

In Vivo
Animal model
Formulation & Dosage
ReferencesJ Biomol Screen. 2012 Aug;17(7):885-99; Mol Cell Endocrinol. 2012 Apr 4;351(2):199-207; J Cell Physiol. 2012 May;227(5):1992-2002.
生物活性


Assessment of potency of selected hits in a panel of kinases using the luminescence ADP production kinase assay. JJ Biomol Screen. 2012 Aug;17(7):885-99.



Assessment of the selective anti-proliferative effect of confirmed positives toward EGFR mutant cell lines. J Biomol Screen. 2012 Aug;17(7):885-99.


Assessment of potency of selected hits in a panel of kinases using the luminescence ADP production kinase assay. J Biomol Screen. 2012 Aug;17(7):885-99.